File downloaded on 2026-11-08
Source URL: https://medicines.health.europa.eu/veterinary/en/600000047348

Anthelmin Plus XL Tablets for dogs

Authorised

- Febantel
- Pyrantel embonate
- Praziquantel

Product identification

Medicine name:
Anthelmin Plus XL Tablets for dogs

Active substance:
Febantel

Pyrantel embonate

Praziquantel

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Febantel

525.00 milligram(s) / 1.00 Tablet

Pyrantel embonate
504.00 milligram(s) / 1.00 Tablet

Praziquantel
175.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP52AC55

Legal status of supply:
Veterinary medicinal product not subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Ireland

Available in:
Ireland

Package description:
OPA/Al/PVC-Al blister.Cardboard box containing 102 tablets.
OPA/Al/PVC-Al blister.Cardboard box containing 100 tablets.
OPA/Al/PVC-Al blister.Cardboard box containing 60 tablets.
OPA/Al/PVC-Al blister.Cardboard box containing 50 tablets.
OPA/Al/PVC-Al blister.Cardboard box containing 30 tablets.
OPA/Al/PVC-Al blister.Cardboard box containing 24 tablets.
OPA/Al/PVC-Al blister.Cardboard box containing 12 tablets.
OPA/Al/PVC-Al blister.Cardboard box containing 10 tablets.
OPA/Al/PVC-Al blister.Cardboard box containing 4 tablets.
OPA/Al/PVC-Al blister.Cardboard box containing 2 tablets.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
KRKA tovarna zdravil d.d. Novo mesto

Marketing authorisation date:
1/05/2015

Manufacturing sites for batch release:
Krka-Farma d.o.o.
KRKA tovarna zdravil d.d. Novo mesto

Responsible authority:
Health Products Regulatory Authority

Authorisation number:
VPA10774/033/002

Date of authorisation status change:
1/05/2015

Reference member state:
Ireland

Procedure number:
IE/V/0538/002

Concerned member states:
Belgium Bulgaria Finland Italy Netherlands Portugal Spain
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

Combined File of all Documents